Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives

Boroumand, N. and Saghi, H. and Avan, A. and Bahreyni, A. and Ryzhikov, M. and Khazaei, M. and Hassanian, S. M. (2018) Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives. Journal of Pharmacy and Pharmacology, 70 (2). pp. 151-158.

[img] Text
Therapeutic potency of heat-shock protein-90 pharmacological inhibitors in the treatment of gastrointestinal cancer, current status and perspectives.pdf

Download (316kB)

Abstract

Objectives: Heat-shock protein-90 (HSP90) chaperone machinery is critical to the folding, stability and activity of several client proteins including many responsible for tumour initiation, progression and metastasis. Overexpression of HSP90 is correlated with poor prognosis of GI cancer. Key findings: Pharmacological inhibitors of HSP90 suppress tumorigenic effects of HSP90 by suppressing angiogenesis, survival, metastasis and drug resistance in GI cancer. This review summarizes the role of HSP90 inhibitors in the treatment of GI cancer. Summary: We have presented different antitumour mechanisms of HSP90 inhibitors in cancer treatment. Suppression of HSP90 signalling via specific and novel pharmacological inhibitors is a potentially novel therapeutic approach for patients with GI cancer for a better understanding and hence a better management of this disease. © 2017 Royal Pharmaceutical Society

Item Type: Article
Additional Information: Cited By :5 Export Date: 16 February 2020 CODEN: JPPMA Correspondence Address: Khazaei, M.; Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical SciencesIran; email: KhazaeiM@mums.ac.ir
Uncontrolled Keywords: gastrointestinal cancer heat-shock protein-90 pharmacological inhibitors aflibercept alpelisib alvespimycin antineoplastic agent celastrol dactolisib ganetespib geldanamycin heat shock protein 90 heat shock protein 90 inhibitor imatinib ld 053 luminespib oxaliplatin placebo radicicol retaspimycin sunitinib tanespimycin trastuzumab unclassified drug xl 888 angiogenesis inhibitor angiogenesis antineoplastic activity apoptosis bile duct carcinoma cancer survival carcinogenesis colon cancer colorectal cancer digestive system cancer drug potency drug treatment failure gastrointestinal carcinoma gastrointestinal stromal tumor human nonhuman pancreas cancer protein function rectum cancer Review signal transduction soft tissue sarcoma stomach cancer animal antagonists and inhibitors cell motion drug effect drug resistance metabolism metastasis neovascularization (pathology) pathology stomach tumor Angiogenesis Inhibitors Animals Cell Movement Drug Resistance, Neoplasm HSP90 Heat-Shock Proteins Humans Neoplasm Metastasis Neovascularization, Pathologic Stomach Neoplasms
Subjects: WI Digestive System
QV pharmacology
QZ pathology-neoplasms-Genetics
Divisions: Mashhad University of Medical Sciences
Depositing User: lib2 lib2 lib2
Date Deposited: 06 Jun 2020 03:52
Last Modified: 06 Jun 2020 03:52
URI: http://eprints.mums.ac.ir/id/eprint/17240

Actions (login required)

View Item View Item